38.98
1.19%
0.46
プレマーケット:
31.51
-7.47
-19.16%
前日終値:
$38.52
開ける:
$38.83
24時間の取引高:
332.83K
Relative Volume:
0.90
時価総額:
$2.97B
収益:
$13.17M
当期純損益:
$-199.06M
株価収益率:
-14.23
EPS:
-2.74
ネットキャッシュフロー:
$-156.53M
1週間 パフォーマンス:
-1.69%
1か月 パフォーマンス:
+0.91%
6か月 パフォーマンス:
-8.78%
1年 パフォーマンス:
-10.94%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
名前
Xenon Pharmaceuticals Inc
セクター
電話
(604) 484-3300
住所
200 - 3650 GILMORE WAY, BURNABY
XENE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.98 | 2.97B | 13.17M | -199.06M | -156.53M | -2.74 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-10-01 | 開始されました | H.C. Wainwright | Buy |
2024-01-04 | 開始されました | Citigroup | Buy |
2023-12-08 | 開始されました | Robert W. Baird | Outperform |
2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
2023-04-25 | 開始されました | Cantor Fitzgerald | Overweight |
2022-12-14 | 開始されました | Goldman | Buy |
2022-12-12 | 開始されました | Cowen | Outperform |
2022-11-28 | 開始されました | Wells Fargo | Overweight |
2022-10-19 | 開始されました | Raymond James | Outperform |
2022-08-29 | 開始されました | BofA Securities | Buy |
2022-07-21 | 開始されました | JP Morgan | Overweight |
2021-10-28 | 開始されました | RBC Capital Mkts | Outperform |
2020-10-02 | 開始されました | SVB Leerink | Outperform |
2020-07-21 | 開始されました | Needham | Buy |
2020-06-01 | 再開されました | Jefferies | Buy |
2020-03-25 | 開始されました | Wedbush | Outperform |
2020-01-08 | 開始されました | William Blair | Outperform |
2019-09-20 | 開始されました | Guggenheim | Buy |
2018-08-08 | 繰り返されました | Stifel | Buy |
2017-03-13 | 開始されました | Jefferies | Buy |
2016-10-21 | 開始されました | Stifel | Buy |
2016-09-26 | 開始されました | Guggenheim | Buy |
2016-04-14 | 繰り返されました | Jefferies | Buy |
2015-10-30 | 再開されました | Jefferies | Buy |
2014-12-02 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Xenon Pharmaceuticals Inc. Announces Cessation of Christopher Von Seggern as Chief Commercial Office - Marketscreener.com
Barclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Barclays PLC Acquires 13,903 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential - Seeking Alpha
XENE Crosses Above Key Moving Average Level - Nasdaq
Xenon Pharmaceuticals Inc (XENE-Q) QuotePress Release - The Globe and Mail
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Xenon Outlines Key Corporate Milestone Opportunities for 2025 - The Manila Times
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Dravet Syndrome Thereapeutics Market Size, Future Consumer Behavior and Market Dynamics (2024-2034) - 100×100 Música
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference - TipRanks
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
JPMorgan Chase & Co. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
JPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Stifel Financial Corp Has $849,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals CFO sells shares worth $770,911 - Investing.com
Xenon Pharmaceuticals CFO sells shares worth $770,911 By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals participates in a conference call with William Blair - Nasdaq
(XENE) Trading Advice - Stock Traders Daily
Citigroup Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - MSN
Lord Abbett & CO. LLC Trims Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook - Investing.com India
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright - Defense World
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? - MSN
XENE Makes Notable Cross Below Critical Moving Average - Nasdaq
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from HC Wainwright - MarketBeat
Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Two Sigma Advisers LP Buys 64,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
(XENE) Technical Data - Stock Traders Daily
Point72 Asset Management L.P. Sells 98,732 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):